We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Approves Purdue Pharma’s Abuse-Deterrent Painkiller

FDA Approves Purdue Pharma’s Abuse-Deterrent Painkiller

July 29, 2014

The FDA approved only the second extended-release opioid painkiller to feature abuse-deterrent properties, and hinted that future products with such technologies could receive faster regulatory reviews.

Purdue Pharma’s Targiniq ER (oxycodone HCl and naloxone HCl extended-release tablets) was approved to treat severe pain that requires daily care and where alternative treatments aren’t enough, the FDA said in a press release.

The drug’s inclusion of naloxone is designed to deter abuse, the agency said.

“When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less liked by abusers than oxycodone alone,” the FDA said. “Targiniq ER can still be abused, including when taken orally, which is currently the most common way oxycodone is abused.”

The FDA has asked the Stamford, Conn., drugmaker to conduct postmarket studies on Targiniq’s abuse potential and the effects of the abuse-deterrent features, a new requirement for all manufacturers of extended-release/long-acting opioids. The only other extended-release formulation is Purdue Pharma’s blockbuster Oxycontin (oxycodone HCl).

The agency is actively encouraging drugmakers to pursue abuse-deterrent formulations in their painkillers, and may grant priority review status or use other expedited pathways for such products, spokeswoman Morgan Liscinsky said.

In addition, the FDA has said it might support longer market exclusivity for products that use packaging, storage and disposal systems or technologies to thwart abusers.

The enticements come as the FDA continues to take heat from lawmakers for approving Zogenix’s Zohydro ER (hydrocodone bitrate) last fall. The single-entity hydrocodone painkiller was approved without abuse-deterrent technology and over objections from FDA advisors. Various lawmakers contend that Zohydro is a prime target for abuse.

In the FDA’s fiscal 2015 funding package, House appropriators took the unusual step of withholding $20 million in funds until the agency finalizes January 2013 guidance on abuse-deterrent opioids. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing